AU2020300543A1 - System for enhancing therapeutic compliance of the anti-cancer compound E7766 - Google Patents

System for enhancing therapeutic compliance of the anti-cancer compound E7766 Download PDF

Info

Publication number
AU2020300543A1
AU2020300543A1 AU2020300543A AU2020300543A AU2020300543A1 AU 2020300543 A1 AU2020300543 A1 AU 2020300543A1 AU 2020300543 A AU2020300543 A AU 2020300543A AU 2020300543 A AU2020300543 A AU 2020300543A AU 2020300543 A1 AU2020300543 A1 AU 2020300543A1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
patient
inhibitor
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020300543A
Other languages
English (en)
Inventor
Vaishali DIXIT
Rongrong JIANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of AU2020300543A1 publication Critical patent/AU2020300543A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020300543A 2019-07-01 2020-07-01 System for enhancing therapeutic compliance of the anti-cancer compound E7766 Pending AU2020300543A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962869389P 2019-07-01 2019-07-01
US62/869,389 2019-07-01
PCT/US2020/040515 WO2021003279A1 (en) 2019-07-01 2020-07-01 System for enhancing therapeutic compliance of the anti-cancer compound e7766

Publications (1)

Publication Number Publication Date
AU2020300543A1 true AU2020300543A1 (en) 2022-02-24

Family

ID=71895194

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020300543A Pending AU2020300543A1 (en) 2019-07-01 2020-07-01 System for enhancing therapeutic compliance of the anti-cancer compound E7766

Country Status (10)

Country Link
US (1) US12564600B2 (cg-RX-API-DMAC7.html)
EP (1) EP3993809B1 (cg-RX-API-DMAC7.html)
JP (1) JP7704690B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220029717A (cg-RX-API-DMAC7.html)
CN (1) CN114599374A (cg-RX-API-DMAC7.html)
AU (1) AU2020300543A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021026876A2 (cg-RX-API-DMAC7.html)
CA (1) CA3145824A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022000052A (cg-RX-API-DMAC7.html)
WO (1) WO2021003279A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4398901A1 (en) 2021-09-09 2024-07-17 Eisai R&D Management Co., Ltd. Biomarkers for sting agonists and methods of using the same
CN115512788B (zh) * 2022-09-16 2023-08-08 山东大学 预测SGLTi人体暴露量及靶蛋白抑制率的方法及系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2446893A1 (en) 2010-11-01 2012-05-02 Bergen Teknologioverføring AS Use of nontoxic cyclic peptides to block transport via OATP1B1/ OATP1B3-related proteins, for the treatment of cancer cells expressing such transporters
WO2013169616A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmacokinetic modulation with alisporivir
BR112017018861A2 (pt) 2015-03-04 2018-04-24 Board Of Regents, The Unibersity Of Texas System métodos para tratar câncer mantendo perda hemizigótica de tp53
MX2018010850A (es) 2016-03-10 2019-05-15 Univ Johns Hopkins Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos.
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
WO2019004466A1 (ja) 2017-06-30 2019-01-03 興和株式会社 医薬
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐

Also Published As

Publication number Publication date
BR112021026876A2 (pt) 2022-02-22
CA3145824A1 (en) 2021-01-07
JP2022538898A (ja) 2022-09-06
EP3993809B1 (en) 2024-10-09
US20220304982A1 (en) 2022-09-29
EP3993809A1 (en) 2022-05-11
MX2022000052A (es) 2022-04-06
CN114599374A (zh) 2022-06-07
JP7704690B2 (ja) 2025-07-08
WO2021003279A1 (en) 2021-01-07
US12564600B2 (en) 2026-03-03
KR20220029717A (ko) 2022-03-08

Similar Documents

Publication Publication Date Title
Persiani et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose
AU2017315357B2 (en) Combination therapies for the treatment of hepatocellular carcinoma
HK1204998A1 (en) Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
JP7665700B2 (ja) 肝細胞癌の治療のための併用療法
EP3993809B1 (en) System for enhancing therapeutic compliance of the anti-cancer compound e7766
EP3454898B1 (en) Drug combinations for reducing cell viability and/or cell proliferation
RU2820595C2 (ru) Система для повышения степени соблюдения терапевтической схемы с противораковым соединением e7766
RU2787993C2 (ru) Комбинированные терапии для лечения гепатоцеллюлярной карциномы